Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5.

Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG. · 2015

Read Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. by Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4288171.txt.

Introduction

Yue Huang and ten co-authors found that a common pain drug blocks one RNA editing enzyme but not its close cousin. Their study appeared in Nucleic Acids Research in 2015. Two human enzymes, FTO and ALKBH5, remove a chemical mark called m6A from messenger RNA, and telling them apart with a drug had proved hard.

Meclofenamic acid, a known anti-inflammatory drug, blocked FTO while leaving ALKBH5 largely alone. Crystal structures showed how the drug sits in FTO and why the cousin escapes. Treated cells gained more of the m6A mark on their RNA. The compound gives researchers a probe for FTO's role in obesity linked biology and in RNA control.

Catalog record

CREATORHuang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4288171

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 By Yue Huang, Jingli Yan, Qi Li, Jiafei Li, Shouzhe Gong, Hu Zhou, Jianhua Gan, Hualiang Jiang, Gui-Fang Jia, Cheng Luo, Cai-Guang Yang Published in: Nucleic Acids Research DOI: 10.1093/nar/gku1276 ABSTRACT Two human demethylases, the fat mass and obesity-associated (FTO) enzyme and ALKBH5, oxidatively demethylate abundant N6-methyladenosine (m6A) residues in mRNA. Achieving a method for selective inhibition of FTO over ALKBH5 remains a challenge, however. Here, we have identified meclofenamic acid (MA) as a highly selective inhibitor of FTO. MA is a non-steroidal, anti-inflammatory drug that mechanistic studies indicate competes with FTO binding for the m6A-containing nucleic acid. The structure of FTO/MA has revealed much about the inhibitory function of FTO. Our newfound understanding, revealed herein, of the part of the nucleotide recognition lid (NRL) in FTO, for example, has helped elucidate the principles behind the selectivity of FTO over ALKBH5. Treatment of HeLa cells with the ethyl ester form of MA (MA2) has led to elevated levels of m6A modification in mRNA. Our collective results highlight the development of functional probes of the FTO enzyme that will (i) enable future biological studies and (ii) pave the way for the rational design of potent and specific inhibitors of FTO for use in medicine. INTRODUCTION The methylation of internal adenosines at the N6 position (m6A) in messenger RNA (mRNA) was first observed several decades ago (1,2). A grasp of its regulatory function was missing, however, until the discovery of the fat mass and obesity-associated (FTO) enzyme in 2011. An m6A demethylase, FTO, was shown to regulate cellular levels of endogenous m6A residues, which strongly suggested that the m6A modification in mRNA is reversible and might be subject to dynamic regulation (3). The existence of the m6A demethylase FTO and the demonstration of the dynamic regulation of the levels of m6A have stimulated explorations of m6A modifications and related enzymes. Researchers have uncovered a wealth of unequivocal evidence for m6A function. The identification and characterization of the m6A methyltransferase tricomplex (METTL3–METTL14–WTAP) further highlights the biological significance of m6A methylation (4,5). The physiological relevance of this modification remains unclear, however. Two recent RNA ‘methylome’ studies have provided a map of m6A-modified mRNAs (6,7). Both found that the ubiquitous m6A modification plays a fundamental regulatory role in gene expression. In addition, binding proteins selectively recognize the dynamic m6A modification, research shows, in order to regulate translation status and the lifetime of mRNA (8). High-resolution mapping has revealed that methylation of adenosine to m6A in mRNA is particularly important for yeast meiosis (9). These studies have provided new insights into the distribution and functional role of m6A in mRNA (10,11). FTO belongs to the family of Fe2+ and 2-oxoglutarate (2OG) dependent AlkB dioxygenases (12) and contributes to non-syndromic human obesity (13). Besides the internal m6A substrates in mRNA, FTO also oxidatively demethylates N3-methylthymine (dm3T) in single-stranded (ss) DNA and N3-methyluridine (m3U) in ssRNA in vitro (14), but has relatively lower activities compared to other AlkB family enzymes that catalyze a wide range of oxidative reactions (15–19). The FTO gene was initially shown to influence human obesity and energy utilization (20,21). In addition, reports indicate the involvement of the FTO protein itself in various diseases (22–26). Such discoveries make FTO an increasingly interesting target with respect to its functional links to human diseases. Another member of the AlkB family, ALKBH5, was also identified as an m6A demethylase of mRNA using Fe2+ and cofactor 2OG, which together function to oxidatively remove the methyl group in m6A-containing substrates (27). Both FTO and ALKBH5 are localized to nuclei and colocalize with nuclear speckles, indicating the effects of methylation on splicing. Indeed, knockdown of the ALKBH5 gene was shown to affect splicing in tissue culture cells, and displayed a sterility phenotype in male mice. The discovery of these two m6A demethylases within the scientific community highlights the importance of m6A modification in basic biology and human disease. Studies that focus on the inhibition of m6A demethylation will likely (i) shed light on the science of ‘RNA epigenetics’ in chemical biology and (ii) hold promise for future therapeutic developments (28,29). The functions and mechanistic studies of Escherichia coli AlkB (30–33), and its human homologs, ALKBH1-8 (34–36), greatly facilitate the development of inhibitors targeting m6A demethylases. Of particular note is a strategy that involves a 2OG-tethering strategy of simultaneously occupying both the 2OG- and substrate-binding sites. The practice of linking 2OG derivatives with the substrate analogs has been successfully applied to the development of selective inhibitors of histone demethylases containing a jumonji domain (37–39). Later on, researchers have applied a similar strategy in order to develop the inhibitors for the AlkB enzyme with success (40). Interestingly, some of the inhibitors have been shown to be selective over other 2OG oxygenases in vitro. The major concern here, however, is that these inhibitors are derivatives of 2OG, and therefore cellular 2OG might compete with them. We and others are working concurrently on the development of FTO inhibitors (41). Our initial steps have led to the identification of the natural product rhein as the first inhibitor of FTO through structure-based virtual screening (42). Rhein, unlike the generic inhibitors of either chemical mimics of 2OG or chelators of iron (43), competitively disrupts FTO from binding to the m6A substrate, and promotes the thermal stability of FTO by directly binding. Rhein also actively increases cellular levels of m6A in mRNA. The structural complex shows that rhein does indeed bind to the nucleic acid-binding site (44). However, rhein shows little selectivity for the AlkB subfamily, which eclipses its utility as a specific functional probe of FTO inside the cell. The 2OG-tethering strategy was also used to develop the cell active FTO inhibitors; during the revision of this work, these inhibitors proved highly selective in vitro for the AlkB subfamily. In vivo selectivity remains unclear, however (45). In order to avoid competition with internal 2OG, we employed an alternative approach to the identification of selective inhibitors of FTO. We performed a high-throughput fluorescence polarization (FP) assay to compare the differences in the displacement of m6A-containing ssDNA binding to FTO and ALKBH5, respectively, in the presence of compounds. This screening led directly to the discovery of meclofenamic acid (MA) that specifically inhibits FTO over ALKBH5. Herein, we focus on a mechanistic study of the selective inhibition of m6A demethylase. Our results will create opportunities for understanding the development of specific functional probes that may target FTO for biological and therapeutic purposes. MATERIALS AND METHODS Protein expression and purification The expression and purification of FTOΔN31 (encoding for His-tag human FTO with N-terminal 31 residues truncated) was modified from previously reported methods (14). E. coli BL21(DE3) cells transformed with the pET28a-FTOΔN31 plasmids were grown at 37ºC to A600 0.6–0.8 and induced by 0.5 mM Isopropyl β-D-1-thiogalactopyranoside at 16ºC for 16 h. The cell pellets were harvested and stored at −80ºC. The cells were resuspended and sonicated in 20 mM Tris-HCl, pH 8.0, 300 mM NaCl in the presence of 5% glycerol. The lysate was centrifuged and the supernatant was loaded onto a 5 ml HisTrapTM HP column (GE Healthcare). The column was allowed to reach equilibrium with binding buffer (20 mM Tris-HCl,

Read the complete text